(EN) The invention provides an application of taurolidine in virus resistance. Specifically, the invention provides use of the taurolidine or a derivative thereof, a prodrug, a solvate or a pharmaceutically acceptable salt thereof, or a composition containing the taurolidine or the derivative thereof, the prodrug, the solvate or the pharmaceutically acceptable salt thereof in preparation of antiviral drugs. Research results show that the taurolidine can significantly inhibit influenza virus and coronavirus at a cellular level. In addition, in-vivo experiments prove that taurolidine has a remarkable protection effect on lungs and can prolong the survival time of mice infected with influenza viruses or SARS-CoV-2 viruses. Therefore, the taurolidine can be used for preventing and treating lung diseases caused by the influenza virus or the coronavirus. The research result of the application expands the efficacy range of the taurolidine, and provides a research basis and opens up a new direction for research and development of drugs for preventing or treating pulmonary infection caused by the viruses.
(ZH) 本申请提供了牛磺罗定在抗病毒中的应用。具体地，本申请提供牛磺罗定或其衍生物、前药、溶剂合物或药学上可接受的盐、或含有牛磺罗定或其衍生物、前药、溶剂合物或药学上可接受的盐的组合物在制备抗病毒药物中的用途。研究结果显示，牛磺罗定在细胞水平上能够显著抑制流感病毒和冠状病毒。另外，体内实验证实牛磺罗定对肺脏具有显著的保护作用，能延长流感病毒或SARS‑CoV‑2病毒感染小鼠的生存时间。表明牛磺罗定可用于流感病毒或冠状病毒引起的肺部疾病的预防和治疗。本申请的研究结果拓展了牛磺罗定的功效范围，为预防或治疗由病毒引起肺部感染药物的研发提供了研究基础和开辟了新方向。
